Evolocumab trial could reshape how doctors treat high-risk cholesterol patients
A new ACC/AHA dyslipidemia guideline and editorial argue that guideline development is rigorous but can lag behind fast-moving science, using the VESALIUS-CV trial as a clear example. The trial showed…